Original Article
Prokinetic effects of large-dose lubiprostone on gastrointestinal transit in dogs and its mechanisms

Jun Song¹,², Jieyun Yin², Xiaohong Xu², Jiande Chen¹,²

¹Division of Gastroenterology, University of Texas Medical Branch, Galveston, Texas; ²Ningbo Pace Translational Medical Research Center, Beilun, Ningbo, China; ³Department of Gastroenterology, Union Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China

Received December 17, 2014; Accepted February 24, 2015; Epub March 15, 2015; Published March 30, 2015

Abstract: Objective: To systemically explore effects of large dose of lubiprostone on gastrointestinal (GI) transit and contractions and its safety in dogs. Methods: 12 healthy dogs were studied. 6 dogs were operated to receive duodenal cannula and colon cannula and the other 6 dogs received gastric cannula. Lubiprostone was orally administrated at a dose of 24 µg or 48 µg 1 hr prior to the experiments. Gastric emptying (GE) of solids and small bowel transit were evaluated by collecting the effluents from the duodenal cannula and from the colon cannula. Gastric accommodation was measured by barostat. Gastric and intestinal contractions were by manometry. Colon transit was by X-ray pictures. Results: 1) Lubiprostone 48 µg not 24 µg accelerated GE. Atropine could block the effect; 2) Average motility index (MI) of gastric antrum in lubiprostone 48 µg session was significantly higher in both fasting state (P = 0.01) and fed state (P = 0.03). Gastric accommodation was not significantly different; 3) Lubiprostone 48 µg accelerated small bowel and colon transit. Atropine could block the effect on small bowel transit; 4) Lubiprostone 48 µg increased postprandial small bowel MI (P = 0.0008) and colon MI (P = 0.002). 5) No other adverse effects except for diarrhea were observed. Conclusion: Acute administration of lubiprostone at a dose of 48 µg accelerates GI motility and enhances GI contractions in the postprandial state. The findings suggest that lubiprostone may have an indirect prokinetic effects on the GI tract and vagal activity may be involved. Lubiprostone may be safely used.

Keywords: Constipation, gastric accommodation, gastrointestinal motility, lubiprostone

Introduction
Chronic constipation is a common clinical problem. 12-19% of the overall population experiences chronic constipation [1, 2]. In 2006 and 2008, lubiprostone, a bicyclic fatty acid was approved by the US Food and Drug Administration to treat idiopathic chronic constipation and irritable bowel syndrome with predominant constipation (IBS-C). Lubiprostone became one of the few prescription drugs approved for IBS-C in the U.S.A. Lubiprostone is a selective type-2 chloride channel (CIC-2) activator. It can increase chloride ion transport and fluid secretion into the intestinal lumen to treat constipation [3, 4]. However, few studies have reported its effects on gastrointestinal transit and contractions. No study on effect of lubiprostone on gastric accommodation, gastric antrum contractions and small bowel contractions was reported. An in-vitro study showed that lubiprostone could cause concentration-dependent contractions of gastric longitudinal muscle and circular muscle preparations via the EP₄ receptor in rats and humans [5]. Cuppoletti et al showed that lubiprostone induced uterine smooth muscle membrane hyperpolarization mediated through lubiprostone’s highly selective activity on CIC-2 channels located on smooth muscle cells [6]. These studies suggest that lubiprostone may also have a prokinetic effect on gastrointestinal motility.

This study aimed to systematically investigate possible effects of lubiprostone on contractions and transit of the entire gastrointestinal tract using a well-established canine model [7, 8]. We chose the doses of 24 µg or 48 µg of lubiprostone that is the standard dose in human and the larger dose in dogs to explore its prokinetic effects and its safety.
Prokinetic effects of lubiprostone

Table 1. Gastric solid emptying (%) in different sessions (mean ± SD) (ANOVA P = 0.03)

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Control</th>
<th>Lub 24 µg</th>
<th>Lub 48 µg</th>
<th>Lub 48 µg plus atropine</th>
<th>Atropine</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>1.3 ± 0.6</td>
<td>1.3 ± 0.4</td>
<td>2.2 ± 0.5*</td>
<td>0.3 ± 0.1*</td>
<td>0.2 ± 0.1*</td>
</tr>
<tr>
<td>30</td>
<td>6.9 ± 2.2</td>
<td>7.5 ± 3.8</td>
<td>13.0 ± 3.7*</td>
<td>1.6 ± 0.8*</td>
<td>0.8 ± 0.2*</td>
</tr>
<tr>
<td>45</td>
<td>15.5 ± 4.3</td>
<td>17.6 ± 5.6</td>
<td>23.8 ± 4.9*</td>
<td>3.4 ± 1.5*</td>
<td>2.2 ± 0.7*</td>
</tr>
<tr>
<td>60</td>
<td>25.6 ± 6.5</td>
<td>28.7 ± 7.5</td>
<td>37.6 ± 7.0*</td>
<td>6.8 ± 2.8*</td>
<td>3.7 ± 0.7*</td>
</tr>
<tr>
<td>90</td>
<td>42.6 ± 7.4</td>
<td>45.10.6</td>
<td>58.6 ± 8.4*</td>
<td>13.8 ± 5.1*</td>
<td>9.8 ± 2.3*</td>
</tr>
<tr>
<td>120</td>
<td>53.1 ± 5.8</td>
<td>59.9 ± 9.4</td>
<td>72.2 ± 7.7*</td>
<td>24.7 ± 7.7*</td>
<td>24.1 ± 6.0*</td>
</tr>
<tr>
<td>150</td>
<td>64.0 ± 5.6</td>
<td>69.4 ± 7.5</td>
<td>79.6 ± 6.8*</td>
<td>39.1 ± 8.7*</td>
<td>42.9 ± 8.6*</td>
</tr>
<tr>
<td>180</td>
<td>68.9 ± 6.6</td>
<td>74.9 ± 6.6</td>
<td>83.3 ± 6.6*</td>
<td>53.4 ± 9.5*</td>
<td>54.9 ± 9.6*</td>
</tr>
</tbody>
</table>

Footnotes: Lub = lubiprostone; * P < 0.05 vs. Control; P > 0.05: atropine session vs. atropine plus lubiprostone 48 µg at any time points; P < 0.05 Control, lubiprostone 24 µg, atropine, lubiprostone 48 µg plus atropine vs. lubiprostone 48 µg at any time points.

Methods

Animal preparation

Twelve healthy female hound dogs (2-3 years old, 19-26 kg) were studied. The dogs were operated under general anesthesia (with initial intravenous infusion of 5 mg/kg thiopental sodium and maintained on 1.5% isoflurane inhalation in 1:1 oxygen-nitrous oxide carrier gases) using a previously established method [9-11]. Laparotomy was performed. Two cannulas were placed in each of six dogs, one in the duodenum 10 cm distal to the gastric pylorus and the other in the ascending colon 5 cm distal to the cecum. A gastric cannula was placed in gastric anterior wall 10 cm above the pylorus in each of the other six dogs [12]. All dogs were given two weeks to recover from the surgery and all experiments were performed in the conscious state with the animal placed on an experimental table and slightly restrained. All dogs were free from any drugs within one week and were fasted overnight prior to the experiment. The protocol has been approved by the Animal Use and Care Committee of the University of Texas Medical Branch at Galveston.

Effects and mechanisms of lubiprostone on gastric solid emptying and small intestinal transit

The experiment was performed in five randomized sessions: control, lubiprostone (Amitiza, 24 µg/capsule, Sucampo Pharmaceuticals, Chicago, IL) 24 µg, lubiprostone 48 µg, atropine, atropine plus lubiprostone 48 µg. 6 dogs with duodenal and colon cannula were used. Lubiprostone or placebo was orally administered 1 hr prior to the experiment. The dosage and timing of dosing were based on previous studies and the T<sub>1/2</sub> (1.73-2.98 hr) and T<sub>max</sub> (2.38 hr) of lubiprostone [13, 14]. Atropine of 0.2 mg/kg was intravenously administered at the beginning of the experiment in atropine or atropine plus lubiprostone session and the dose was in the previous studies [15, 16]. Gastric emptying (GE) was assessed by collecting gastric effluent from the duodenal cannula following ingestion of one can of dog food (Pedigree, Chopped Chicken). The collection was done at 15, 30, 45, 60, 90, 120, 150, 180 minutes after feeding for the lubiprostone sessions. For the control session, the collection lasted until no chyme containing any solid was seen. For every collection, the effluent was homogenized and the volume was recorded, 10 ml of sample was kept and the left effluent was immediately injected back into small bowel from the duodenal cannula. The samples were centrifuged, the liquid supernatant was discarded, and the remaining samples were removed from tube, spread on paper plates to air dry until the weight remained unchanged and then weighed in grams. The dried weight of every collection was calculated. The percentage of GE was defined as the ratio between the dried weight of the collection and the total dried weight of all samples in the control session. The percentage of GE at each time point is the accumulative percentage of GE up to that time point [11, 16, 17]. In control session, placebo capsule (vitamin E) was given orally.

Small bowel transit was measured at the same time when GE was monitored as follows: Immediately after feeding, 15 mg of phenol red mixed with 30 ml of saline was injected into the small intestine from the duodenal cannula. The colon cannula was opened and the effluent was collected every 5 minutes. The time when the phenol red began to appear from the colon cannula was confirmed by spectrophotometer...
Prokinetic effects of lubiprostone

Methods and the time length between the injection of phenol red and the first appearance of phenol red collected from the distal cannula was defined as the small bowel transit time (SBTT).

Effects of lubiprostone on gastric tone and accommodation

Six dogs with gastric cannula were used in this experiment with control and lubiprostone sessions. Lubiprostone 48 µg or placebo was given orally to each dog 1 hr prior to experiment. Antral contractions was measured using one manometric catheter with four pressure sensors attached to a PC polygraph HR system and a microcapillary infusion system (model 8; Medtronic Synectics, Stockholm, Sweden). The catheter was put into the distal stomach to measure the antral motility. After 30 min baseline recording in the fasting state, one can of dog food was provided to each dog and postprandial motility was recorded for 60 minutes. The contractile activity was evaluated by using the mean area under curve (AUC) per second expressed as motility index (MI) computed by Polygram Function Testing Software (Medtronic, Shoreview, MN) [15, 20].

Effects of lubiprostone on small bowel contractions

Six dogs with duodenal cannula were used in the experiment with control and lubiprostone 48 µg sessions. Lubiprostone or the placebo was orally administrated 1 hour prior to the experiment. After the dog was fed with the same food, the manometric recording was made for 60 min using an intra-lumen catheter inserted into the intestine through the duodenum cannula. The catheter contained five manometric sensors at an interval of 5 cm with the computerized electrical barostat device (Distender Series IIR; G & J Electronics Inc., Willowdale, Ontario, Canada) by a double-lumen catheter [18, 19]. The balloon was deflated completely. The minimal distending pressure was determined by inflating the balloon in 1 mmHg increments until a pressure at which evident respiratory excursions were recorded. Gastric tone was recorded at an operating pressure of 2 mmHg higher than the minimal distending pressure [19]. Gastric tone was assessed from the balloon volume. After 30 min baseline recording of gastric tone, one can of food was provided to the dog and gastric tone was recorded for 30 minutes. Gastric accommodation was defined as the difference in average volume between the postprandial period and the fasting period.

Figure 1. Effect of lubiprostone on gastric emptying of solids. Lubiprostone at 48 µg but not 24 µg significantly enhanced gastric solid emptying at any time points. Atropine blocked the effects. P < 0.05 Control, lubiprostone 24 µg, atropine, lubiprostone 48 µg plus atropine vs. lubiprostone 48 µg at any time points. *P < 0.05.

Figure 2. Effects of lubiprostone on gastric antral manometry. Lubiprostone 48 µg significantly increased gastric antral contractions in fasting state (P = 0.01) and in fed state (P = 0.03).
Prokinetic effects of lubiprostone

Effects of lubiprostone on colon transit

Six dogs with colon cannula were involved in the experiment with control and lubiprostone 48 µg sessions. The dog received the placebo/drug orally. Thirty minutes later, one capsule containing 24 radiopaque markers (1.5-5 mm, Sitzmarks-Konsyl Pharmaceuticals, Easton, MD, USA) were placed into the proximal colon via the colon cannula and one can of the same food was fed. The x-rays were taken at 2, 4, and 6 hours post feeding.

Colon transit was determined based on the localization and the number of markers in each x-ray picture using geometric center (GC) value. The GC is the weighted average of counts in the different colonic regions [21]: ascending (AC), hepatic flexure (HC), transverse (TC), splenic flexure (SC), descending (DC), rectosigmoid (RS), and stool. GC = (number in AC x 1 + number in HC x 2 + number in TC x 3 + number in SC x 4 + number in DC x 5 + number in RS x 6 + evacuated number x 7)/24. A high GC value implies faster colonic transit.

Results

Effects and mechanisms of lubiprostone on gastric solid emptying

Lubiprostone 48 µg significantly accelerated GE at all-time points with the largest increase noted at 120 min from 53% in the control session to 72% with the medication. Lubiprostone 24 µg didn’t significantly accelerated GE at all-time points (p > 0.05 vs. control). Lubiprostone 48 µg also had accelerated GE at all-time points compared with lubiprostone at 24 µg (p < 0.05). Atropine blocked the accelerative effect of lubiprostone 48 µg on GE. No difference was found in GE between the atropine session and lubiprostone 48 µg plus atropine session (p > 0.05) (see Table 1 and Figure 1). The finding suggested that vagal mechanism might be involved.

Effects of lubiprostone on gastric tone and accommodation

Lubiprostone 48 µg did not significantly alter gastric accommodation. In the fasting state, the average intragastric balloon volume was 116 ± 14 mL in the control session and 149 ± 18.4 mL with lubiprostone 48 µg (P > 0.05). In
Prokinetic effects of lubiprostone

**Figure 4.** Effect of lubiprostone 48 µg on tracing in small bowel manometry (30 minutes). Lubiprostone 48 µg significantly increased small bowel motility index (P < 0.001 vs. control). The average motility index increased 50% in the lubiprostone 48 µg session. This figure shows representative tracing in one dog.

**Figure 5.** Effect of lubiprostone 48 µg on the geometric center values in colon transit. Lubiprostone 48 µg significantly promoted colon transit at 2, 4, 6 hours after the insertion of the markers and food feeding (*P < 0.05).

Effects of lubiprostone on gastric antral contractions

Postprandial antral contractile activity was significantly increased with lubiprostone 48 µg. Compared with control session, the MI in the lubiprostone session was significantly higher in both fasting state (10.4 ± 0.7 vs. 6.9 ± 0.9, P = 0.01) and fed state (14.8 ± 1.3 vs. 12 ± 0.8, P = 0.03) (**Figure 2**).

Effects and mechanisms of lubiprostone on small bowel transit

Lubiprostone at both 24 µg and 48 µg accelerated small bowel transit (P < 0.05). The small bowel transit time (SBTT) was 137.8 ± 19.3 min in the control session, 71.0 ± 28.9 min in the lubiprostone 24 µg session (P = 0.04 vs. control) and 82.5 ± 31.3 min in the lubiprostone 48 µg session (P = 0.04 vs. control). No difference was noted in the transit time between the two doses of lubiprostone (P > 0.05). Atropine could block the effects of lubiprostone 48 µg on small bowel transit. The SBTT was 208.8 ± 21.8 min in atropine session (P = 0.007 vs. control) and 205.6 ± 15.9 min in lubiprostone 48 µg plus atropine session (P = 0.006 vs. control; P = 0.002 vs. lubiprostone 48 µg). No difference was found between the two groups (P > 0.05) (**Figure 3**).

Effects of lubiprostone on small bowel manometry

Lubiprostone 48 µg enhanced postprandial small bowel motility. The mean MI was 8.8 ± 0.6 in the control session and 13.2 ± 1.5 (P =
Prokinetic effects of lubiprostone

Effects of lubiprostone on colon transit

Lubiprostone 48 µg accelerated colon transit. The GC values in the control session and the Lubiprostone session were 1.9 ± 0.6 and 3.0 ± 0.2 (P = 0.03) at 2 hrs, 3.9 ± 0.5 and 5.1 ± 0.3 (P = 0.03) at 4 hrs and 5.0 ± 0.1 and 5.7 ± 0.2 (P = 0.01) at 6 hrs after the insertion of the markers (ANOVA P < 0.001) (Figure 5).

Effects of lubiprostone on colon manometry

Lubiprostone 48 µg improved postprandial colon contractions. The mean MI was 5.2 ± 0.3 in the control session and 6.5 ± 0.4 in the lubiprostone session (P = 0.002). The mean MI was increased by 26% with lubiprostone. Figure 6 presents typical colon contractile tracing in the postprandial state in the control and lubiprostone sessions.

Side effects

During the experiments, all the dogs were orally administrated with lubiprostone had diarrhea. No vomiting and other abnormal behaviors and adverse events were noted.

Discussion

This study demonstrates that lubiprostone 48 µg accelerated GE, small intestinal and colonic transit in healthy dogs. It enhanced gastric antral, small intestinal and colonic contractions in the postprandial state. It didn't affect gastric accommodation. Lubiprostone 24 µg did not accelerate GE, but accelerated small intestinal transit. Atropine could block the accelerative effects of lubiprostone on GE and small bowel transit. No other side effects except for diarrhea were observed, suggesting lubiprostone might be used in safety.

A number of previous studies have confirmed the safety and efficacy of lubiprostone in treating the patients with idiopathic chronic constipation and irritable bowel syndrome with predominant constipation [9, 22-25]. Lubiprostone is an oral bicyclic fatty acid ClC-2 channel activator that belongs to a new class of drugs called prostanes derived from a metabolite of prostaglandin E₁. ClC-2 channels are distributed throughout the body, including the GI tract (stomach, small intestine, colon), and have several essential functions, including maintaining the membrane potential of the cells, regulating pH and cell volume, and participating in Cl transport and fluid secretion [26-31]. Lubiprostone selectively activates type-2 chloride channels located on intestinal epithelial cells leading to an active efflux of Cl ions into the lumen of the GI tract, followed by Na⁺ ions and then water efflux [3, 32]. Secretion of fluids promotes intestinal transit through stimulation of local receptors sensitive to stretch and disten-
Prokinetic effects of lubiprostone

tion [33, 34]. Although the exact mechanism explaining lubiprostone’s efficacy is not completely understood, its primary action is possibly mediated via this mechanism [32]. However, few studies have been performed examining the effects of lubiprostone on gastrointestinal transit and motor functions.

In clinic, the common dose of lubiprostone is 24 µg twice daily for chronic idiopathic constipation. So we choose the doses of 24 µg and 48 µg to observe its effect on gastrointestinal motility. We found that lubiprostone 48 µg but not 24 µg accelerated GE. Camilleri et al found that lubiprostone 24 µg induced retarded GE in healthy human subjects but did decrease fullness 30 min after the fully satiating meal [35]. The differences of the effects on GE may be explained by the dose. The dose of 48 µg is a larger dose for one dog. We found lubiprostone at 24 µg did not affect GE in the dogs. The result was supported by our gastric antral manometric finding. We found lubiprostone 48 µg could increase gastric antral contractions. Interestingly, we found atropine could block the accelerative effect of lubiprostone on GE. It suggests lubiprostone possibly has an indirect prokinetic effect on stomach involving vagal activity. The specific mechanism isn’t clear. It’s proposed the effect may be via volume reflex. Recent study showed gastric distention-induced efferent chronotropic responses involve both increased parasympathetic and reduced sympathetic activity. The vagal excitatory reflex involves the nucleus ambiguous (NA) and atropine-methyl-bromide completely blocked the reflex [36]. Although there are contradictory studies in vitro regarding the direct activation of smooth muscle or activation of prostaglandin receptors by lubiprostone [5, 6], our finding support an indirect prokinetic effect of lubiprostone. On the other hand, our results found lubiprostone 48 µg couldn’t improve gastric accommodation. The mechanism is not clear. To our knowledge, no previous studies were performed on the effects of lubiprostone on gastric accommodation. Our results in dogs need to be confirmed in clinic, especially at a higher dose.

We found that both lubiprostone 48 µg and 24 µg significantly accelerated small bowel transit. The results are similar to one previous study. Camilleri et al showed that lubiprostone accel-

erated small bowel transit in healthy human subjects [13]. In addition, we found atropine could block the accelerative effect of lubiprostone on small bowel transit, suggesting that lubiprostone may have indirect prokinetic effects by the peristaltic reflux mediated by muscle stretches and mucosal distention caused by fluid secretion. Vagal mechanisms may be involved in the reflux [21]. We further confirmed that lubiprostone enhanced small bowel contractile activity. No previous studies, to our knowledge, have addressed the effects of lubiprostone on small intestinal contractions.

We also found that lubiprostone significantly accelerated colon transit at 2, 4, and 6 hours post-feeding. Camilleri et al also found that lubiprostone accelerated colon transit in human subjects [13]. Our manometric study in the right colon further showed that lubiprostone increased local contractile activity. Sweetser et al found that lubiprostone could not increase contractile activity in the human left colon by placing a barostat-manometric tube under flexible sigmoidoscope [37]. The findings and the current findings suggest that the prokinetic effect of lubiprostone on the right colon possibly play an important role in its acceleration of colon transit. One recent 24-hour colonic manometry study in children patients with constipation also found that oral lubiprostone has a stimulant effects on colonic contraction [38]. Bassil et al showed that lubiprostone caused muscle contractions in rat colon longitudinal muscle and these excitatory effects tended to be inhibited by pretreatment with the EP<sub>1</sub> receptor antagonist [5]. Recently, Jakab RL, et al found that lubiprostone induced contraction of villi and proximal colonic plicae and membrane trafficking of transporters, suppress fluid absorption, and enhance mucus mobilization and mucosal contractility [39]. Consequently, lubiprostone has the prokinetic effects in colon. The mechanisms need further studies.

In conclusion, lubiprostone 48 µg accelerates GE of solids, small bowel transit and colon transit, and enhances gastric antral, small intestinal and colonic contractions in the postprandial state in dogs. Atropine could block the accelerative effect of lubiprostone on GE and small bowel transit, suggesting that lubiprostone may have an indirect prokinetic effects in stomach.
and intestine and vagal mechanism possibly was involved. More studies are needed to investigate the mechanisms involved in the prokinetic effects of lubiprostone.

Disclosure of conflict of interest
None.

Address correspondence to: Dr. Jiande Chen, Ningbo Pace Translational Medical Research Center, Ningbo, China. Tel: 86-574-86818913; Fax: 86-574-86818262; E-mail: chenjiande_nb@163.com; jianchen@utmb.edu

References


[22] Iwa M, Strickland C, Nakade Y, Pappas TN and Takahashi T. Electroacupuncture reduces rec-
Prokinetic effects of lubiprostone


